US 11,814,411 B2
Nucleic acid molecules encoding binding agents to CD40 and 4-1BB (CD137)
Ugur Sahin, Mainz (DE); Friederike Gieseke, Mainz (DE); Isil Altintas, Utrecht (NL); David Satijn, Utrecht (NL); and Paul Parren, Utrecht (NL)
Assigned to BIONTECH SE, Mainz (DE); and GENMAB A/S, Copenhagen (DK)
Filed by BIONTECH SE, Mainz (DE); and GENMAB A/S, Copenhagen (DK)
Filed on Jan. 8, 2021, as Appl. No. 17/144,591.
Application 17/144,591 is a division of application No. 16/582,534, filed on Sep. 25, 2019, granted, now 10,927,181.
Application 16/582,534 is a division of application No. 15/538,419, granted, now 10,457,735, issued on Oct. 29, 2019, previously published as PCT/EP2016/050308, filed on Jan. 8, 2016.
Claims priority of application No. PCT/EP2015/050255 (WO), filed on Jan. 8, 2015.
Prior Publication US 2021/0253725 A1, Aug. 19, 2021
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/2878 (2013.01) [C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01)] 14 Claims
 
1. A nucleic acid molecule encoding a binding agent comprising at least two binding domains, wherein a first binding domain binds to a first receptor of the tumor necrosis factor (TNF) superfamily and a second binding domain binds to a second receptor of the TNF superfamily, wherein the first receptor and the second receptor are different, wherein:
the first binding domain binds to CD40 and is selected from a first group consisting of:
(a) light and heavy chain complementarity determining regions wherein
the heavy chain complementary determining region 1 (HCDR1) includes the amino acid sequence of SEQ ID NO: 2323, the HCDR2 includes the amino acid sequence of SEQ ID NO: 2324 and the HCDR3 includes the amino acid sequence of SEQ ID NO: 2325, and
the light chain complementarity determining region 1 (LCDR1) includes the amino acid sequence of SEQ ID NO: 2326, the LCDR2 includes the amino acid sequence of SEQ ID NO: 2327 and the LCDR3 includes the amino acid sequence of SEQ ID NO: 2328; and
(b) a heavy chain variable domain (VH) having the amino acid sequence of SEQ ID NO: 2321, and a light chain variable domain (VL) having the amino acid sequence of SEQ ID NO: 2322; and
the second binding domain binds to 4-1 BB (CD137) and is selected from a second group consisting of:
(a) light and heavy chain complementarity determining regions wherein
the heavy chain complementary determining region 1 (HCDR1) includes the amino acid sequence of SEQ ID NO: 2297, the HCDR2 includes the amino acid sequence of SEQ ID NO: 2298 and the HCDR3 includes the amino acid sequence of SEQ ID NO: 2299, and
the light chain complementarity determining region 1 (LCDR1) includes the amino acid sequence of SEQ ID NO: 2300, the LCDR2 includes the amino acid sequence of SEQ ID NO: 2301 and the LCDR3 includes the amino acid sequence of SEQ ID NO: 2302;
(b) a heavy chain variable domain (VH) having the amino acid sequence of SEQ ID NO: 2241 and a light chain variable domain (VL) having the amino acid sequence of SEQ ID NO: 2242;
(c) light and heavy chain complementarity determining regions wherein
the heavy chain complementarity determining region HCDR1 includes the amino acid sequence of SEQ ID NO: 2255, the HCDR2 includes the amino acid sequence of SEQ ID NO: 2256 and the HCDR3 includes the amino acid sequence of SEQ ID NO: 2257, and
the light chain complementarity determining region LCDR1 includes the amino acid sequence of SEQ ID NO: 2258, the LCDR2 includes the amino acid sequence of SEQ ID NO: 2259 and the LCDR3 includes the amino acid sequence of SEQ ID NO: 2260;
(d) a heavy chain variable domain (VH) having the amino acid sequence of SEQ ID NO: 2227 and a light chain variable domain (VL) having the amino acid sequence of SEQ ID NO: 2228;
(e) light and heavy chain complementarity determining regions wherein
the heavy chain complementarity determining region HCDR1 includes the amino acid sequence of SEQ ID NO: 2315, the HCDR2 includes the amino acid sequence of SEQ ID NO: 2316 and the HCDR3 includes the amino acid sequence of SEQ ID NO: 2317, and
the light chain complementarity determining region LCDR1 includes the amino acid sequence of SEQ ID NO: 2318, the LCDR2 includes the amino acid sequence of SEQ ID NO: 2319 and the LCDR3 includes the amino acid sequence of SEQ ID NO: 2320; and
(f) a heavy chain variable domain (VH) having the amino acid sequence of SEQ ID NO: 2247 and a light chain variable domain (VL) having the amino acid sequence of SEQ ID NO: 2248.